

AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Pulmonary Arterial Hypertension (PAH) (Pharmacy)

Drug Requested: (select drug below)

Phosphodiesterase Type-5 Inhibitors			
☐ sildenafil 20 mg tablet (generic Revatio®)		☐ sildenafil oral suspension (generic Revatio®)	
☐ tadalafil 20 mg tablet (generic Adcirca® or Alyq®)		☐ Tadliq® (tadalafil) oral suspension	
Endothelin Receptor Antagonists			
☐ ambrisentan (generic Letairis®)	☐ bosentan (generic Tracleer®) tablet	☐ bosentan (generic Tracleer®) dispersible tablet	☐ macitentan (Opsumit®)
Soluble Guanylate Cyclase Stimulator (sGC)			
☐ Adempas® (riociguat)			
Prostacyclin Pathway Agents – Analogues and Receptor Agonist			
☐ Orenitram® (treprostinil)		☐ Tyvaso® (treprostinil) nebulizer solution	
☐ Tyvaso DPI™ (treprostinil)		☐ Uptravi® (selexipag)	
☐ Ventavis® (iloprost)		☐ Yutrepia™ (treprostinil) inhalation powder	
Endothelin Receptor Antagonists + Phosphodiesterase Type-5 Inhibitors			
☐ Opsynvi® (macitentan/tadalafil)			

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

(Continued on next page)

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosage and/or Quantity Limits (Maximum Daily Dosage):

<u>Drug Name</u>	<u>Drug strength/formulation</u>	<u>Quantity (units)</u>	<u>Day Supply</u>	<u>Units/Day</u>
Sildenafil	20 mg tablet	90	30	3
	10 mg/mL oral suspension	180 mL	30	6
Tadalafil	20 mg tablet	60	30	2
<u>Tadliq</u>	20 mg/5 mL oral suspension	300 mL	30	10
Ambrisentan	5 mg & 10 mg tablet	30	30	1
Bosentan	62.5 & 125 mg tablet	60	30	2
Bosentan	32 mg dispersible tablet for oral suspension	120	30	4
Macitentan	10 mg tablet	30	30	1
	Month 1 Titration Pack	1	N/A	N/A
	Month 2 Titration Pack	1	N/A	N/A
	Month 3 Titration Pack	1	N/A	N/A
Adempas	All strengths (0.5, 1, 1.5, 2, & 2.5 mg tablets)	90	30	3
Uptravi	All strengths (200, 400, 600, 800, 1000, 1200, 1400, & 1600 mcg tablets)	60	30	2
	Titration Pack	1	N/A	N/A
Orenitram	All strengths (0.125 mg, 0.25 mg, 1 mg, 2.5 mg, 5 mg tablets)	90	30	3
Tyvaso	1.74 mg/2.9 mL ampule	28	28	1
Tyvaso DPI	16, 32, 48, 64 & 80 mcg cartridges, 32-48, 32-64, 48-64 & 48-80 mcg maintenance kits	1	28	4
	16-32 mcg titration kit & 16-32-48 mcg titration kit	1	N/A	N/A
Yutrepia	26.5 mcg, 53 mcg, 79.5 mcg & 106 mcg inhalation capsules	112	28	4
Ventavis	10 mcg/mL & 20 mcg/mL ampule	270, 1 mL ampules	30	9
Opsynvi	10-20 mg & 10-40 mg tablets	30	30	1

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

SECTION A: Diagnosis Criteria (required for all selected products)

- ☐ Member must meet **ONE** of the following medication-age requirements:
 - ☐ Member is at least 18 years old
 - ☐ For bosentan (generic Tracleer[®], addressed below) requests: Member is at least 3 years old
 - ☐ For sildenafil (generic Revatio), addressed below) requests: Member is at least 1 year old
 - ☐ For Uptravi[®] (selexipag), addressed below) requests: Member is at least 2 years old
- ☐ **For female patients of reproductive potential**, pregnancy has been excluded before initiation of treatment; acceptable methods of contraception will be used during treatment and for 1 month after discontinuing treatment, and pregnancy status will be monitored monthly
- ☐ Provider is a clinician with expertise in treating patients with pulmonary arterial hypertension
- ☐ Member has a diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 [**OR** WHO Group 4, for Adempas[®] (riociguat), addressed below]
- ☐ Diagnosis of PAH has been confirmed by an expert center meeting **ALL** the following criteria:
 - Hemodynamic definitions obtained from a right heart catheterization
 - Medical chart notes and results from the right heart catheterization, laboratory documentation, imaging results, pulmonary function tests, arterial blood gases, are required to be submitted with this request
- ☐ A mean arterial pressure (mPAP) measured ≥ 20 mmHg at rest confirmed by a right heart catheterization
- ☐ A pulmonary artery wedge pressure (PAWP) measured ≤ 15 mmHg
- ☐ A pulmonary vascular resistance (PVR) measured ≥ 2 Woods units

SECTION B: Risk Status Stratification – complete one of the following below

- ☐ **FOR INITIATING PAH THERAPY [APPROVAL LENGTH 6 MONTHS]**
 - ☐ A PAH risk assessment has been completed, and the member's risk status can be considered **ONE** of the following at the time of diagnosis:
 - ☐ Low-risk
 - ☐ Intermediate-risk
 - ☐ High-risk [IV PAH therapy will require prior authorization]
 - ☐ Combination therapy is limited to a two drug regimen from two different therapeutic classes listed below in Section C

OR

(Continued on next page)

☐ **FOR CONTINUING PAH THERAPY [APPROVAL LENGTH 12 MONTHS]**

- ☐ List the Current Treatment Regimen and Duration:

Drug & Date: _____

Drug & Date: _____

Drug & Date: _____

- ☐ Member must meet **ONE** of the following:

- ☐ Member's condition is stable (i.e. not experiencing clinical worsening), or has maintained a low-risk clinical status on current therapy, and regimen detailed above will continue
- ☐ Follow-up to the treatment regimen detailed above resulted in an increase to intermediate or high-risk status and requires escalation in therapy regimen (i.e., combination/addition of agents)

NOTE: IV PAH therapy will require prior authorization

- ☐ Combination therapy will be selected from different therapeutic classes listed below in Section C

SECTION C – Drug Agents

☐ **sildenafil 20 mg (generic Revatio®) tablets or oral suspension**

- ☐ Member's symptomology is determined to be NYHA Functional Class II or III
- ☐ Sildenafil will **NOT** be used concurrently with Adempas® (riociguat) (**verified by chart notes and/or pharmacy paid claims**)
- ☐ Member is **NOT** receiving organic nitrates (e.g., isosorbide mononitrate, isosorbide dinitrate) either regularly or intermittently due to potentiation of the hypotensive effects (**verified by chart notes and/or pharmacy paid claims**)
- ☐ **If requesting oral suspension:** Member's >18 years of age **MUST** have a clinical/medical preclusion to taking oral tablets (medical documentation must be attached to this request for failure)

☐ **tadalafil 20 mg (generic Adcirca® or Alyq®) tablets or Tadliq® (tadalafil) oral suspension**

- ☐ Member's symptomology is determined to be NYHA Functional Class II or III
- ☐ Tadalafil will **NOT** be used concurrently with Adempas® (riociguat) (**verified by chart notes and/or pharmacy paid claims**)
- ☐ Member is **NOT** receiving organic nitrates (e.g., isosorbide mononitrate, isosorbide dinitrate) either regularly or intermittently due to potentiation of the hypotensive effects (**verified by chart notes and/or pharmacy paid claims**)
- ☐ **If requesting Tadliq® oral suspension:** Member's >18 years of age **MUST** have a clinical/medical preclusion to taking oral tablets (**medical documentation must be attached to this request for failure**)

(Continued on next page)

☐ **Adempas®** (riociguat)

☐ **For all Diagnoses:**

- ☐ Adempas will **NOT** be taken in combination with a phosphodiesterase type 5 (PDE-5) inhibitor (**verified by chart notes and/or pharmacy paid claims**)
- ☐ All provider and patient-specific requirements of REMS have been satisfied

☐ **For WHO Group 4 Only:**

- ☐ A diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) categorized as persistent/recurrent, is confirmed
- ☐ Member previously failed surgical treatment (such as a pulmonary endarterectomy) or the member has inoperable CTEPH (**verified by chart notes**)
- ☐ Documentation of ventilation-perfusion scan or pulmonary angiography confirming the diagnosis of CTEPH is attached with this request

☐ **ambrisentan** (generic Letairis®)

NOTE: diagnosis of idiopathic pulmonary fibrosis, including category WHO Group 3 is a contraindication and excluded from therapy with ambrisentan

- ☐ Member's symptomology is determined to be NYHA Functional Class II or III
- ☐ All provider and patient-specific requirements of REMS have been satisfied

☐ **bosentan** (generic Tracleer®)

- ☐ **For adults:** Member's symptomology is determined to be NYHA Functional Class II, III, or IV
- ☐ **For pediatric members ≥ 3 years old:** pulmonary arterial hypertension with idiopathic or congenital etiologies
- ☐ **For generic bosentan (Tracleer®) dispersible tablet requests:** Member is ≥ 3 years of age and ≤ 11 years of age, with a body weight ≥ 4 kg and < 40 kg
- ☐ A baseline liver function test has been obtained and provided prior to initiation of therapy, and will be monitored
- ☐ All provider and patient-specific requirements of REMS have been satisfied

☐ **macitentan** (Opsumit®)

- ☐ Member's symptomology is determined to be NYHA Functional Class II or III
- ☐ Provider has submitted medical chart notes and history detailing a failure in therapy with ambrisentan or bosentan (**medical/clinical documentation to include detailed record of decreases in 6MWD, clinical worsening, decreased exercise ability**)

(Continued on next page)

- ❑ A baseline hemoglobin level has been obtained and provided prior to initiation of therapy, and will be monitored monthly
- ❑ A baseline liver function test has been obtained and provided prior to initiation of therapy, and will be monitored monthly
- ❑ All provider and patient-specific requirements of REMS have been satisfied

❑ **Uptravi®** (selexipag)

- ❑ Member's symptomology is determined to be NYHA Functional Class II or III
- ❑ Uptravi® is being selected as add-on treatment as a result of the member experiencing clinical worsening and increase in risk status on current therapy
- ❑ Uptravi® will be used in combination with an endothelin receptor antagonist and/or a PDE-5 inhibitor (**verified by chart notes and/or pharmacy paid claims**)
- ❑ Uptravi® will **NOT** be taken in combination with a prostanoid/prostacyclin analogue (**verified by chart notes and/or pharmacy paid claims**)

❑ **Orenitram®** (treprostinil)

- ❑ Member's symptomology is determined to be NYHA Functional Class II or III
- ❑ A baseline liver function test has been obtained and provided prior to initiation of therapy, and will be monitored
- ❑ Orenitram® is being selected as add-on treatment as a result of the member experiencing clinical worsening and increase in risk status on current therapy
- ❑ **If currently on an IV Prostacyclin Analogue**, therapy will be transitioned to orenitram and IV PCA will tapered

❑ **Tyvaso®** (treprostinil), **Tyvaso DPI™** (treprostinil), **Ventavis®** (iloprost), **Yutrepia™** (treprostinil)

- ❑ Tyvaso®, Tyvaso DPI™, Ventavis® or Yutrepia™ will **NOT** be used for monotherapy or for therapy of treatment-naïve PAH patients
- ❑ Tyvaso®, Tyvaso DPI™, Ventavis® or Yutrepia™ is being selected as add-on treatment as a result of the member experiencing clinical worsening and increase in risk status on current therapy
- ❑ Tyvaso®, Tyvaso DPI™, Ventavis® or Yutrepia™ requests: Member's symptomology is determined to be NYHA Functional Class III
- ❑ For Ventavis® requests: Member's symptomology is determined to be NYHA Functional Class III or IV

(Continued on next page)

☐ **Opsynvi®** (macitentan/tadalafil)

- ☐ Member's symptomology is determined to be NYHA Functional Class II or III
- ☐ Opsynvi will **NOT** be used concurrently with Adempas® (riociguat)
- ☐ Member must meet **ONE** of the following:
 - ☐ Provider has submitted medical chart notes and history detailing a failure in therapy with ambrisentan or bosentan (**medical/clinical documentation to include detailed record of decreases in 6MWD, clinical worsening, decreased exercise ability**)
 - ☐ Member is established on dual therapy with single ingredient Opsumit® (macitentan) **AND** tadalafil (generic Adcirca®/Alyq®)
- ☐ Member is **NOT** receiving organic nitrates (e.g., isosorbide mononitrate, isosorbide dinitrate) either regularly or intermittently due to potentiation of the hypotensive effects
- ☐ A baseline hemoglobin level has been obtained and provided prior to initiation of therapy, and will be monitored monthly
 - ☐ A baseline liver function test has been obtained and provided prior to initiation of therapy, and will be monitored monthly
- ☐ All provider and patient-specific requirements of REMS have been satisfied

Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****